This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Citro, G., Cucco, C., Verdina, A. et al. Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Br J Cancer 64, 534–536 (1991). https://doi.org/10.1038/bjc.1991.345
Issue Date:
DOI: https://doi.org/10.1038/bjc.1991.345
This article is cited by
-
Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer
British Journal of Cancer (1999)
-
Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer
Breast Cancer Research and Treatment (1995)
-
Relative cytotoxicities of Adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines
Urological Research (1995)
-
Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target
Cancer Chemotherapy and Pharmacology (1994)
-
Receptor-mediated oligodeoxynucleotides delivery by estradiol and folic acid polylysine conjugates
Cytotechnology (1993)